educratsweb.com >> ASTRAZENECASIGNS MOU WITH INDIAN DIABETES RESEARCH SOCIETY (RSSDI) TO EMPOWER1 CRORE INDIAN DIABETIC PATIENTS BY 2023 - EDUCRATSWEB.COM educratsweb.com >> ASTRAZENECASIGNS MOU WITH INDIAN DIABETES RESEARCH SOCIETY (RSSDI) TO EMPOWER1 CRORE INDIAN DIABETIC PATIENTS BY 2023 - EDUCRATSWEB.COMAstraZenecasigns MoU with Indian Diabetes Research Society (RSSDI) to empower1 Crore Indian Diabetic patients by 2023
· With close to 8 Crore diabetes patients in India, the need for building awareness and research-based effort to providethe much-needed support forearly detection and treatment of Diabetes will go a long way in decreasing the uncontrolled incidence of the disease and associated complications.
26thNov 2020, Mumbai, India:AstraZeneca India (AstraZeneca Pharma India Limited), a leading science-led biopharmaceutical company, today signed a memorandum of understanding with the Research Society for Study of Diabetes in India (RSSDI). This MOUis aimed at digitising and driving correct awareness ofDiabetes amongst people to prevent complications arising from the uncontrolled incidence of the disease.
RSSDI is the largest organisation of Diabetes health care professionals and researchers in Asia with around 6000 members from amongst physicians, diabetologists, endocrinologists, as well as paramedical personnel. The organisation has been instrumental in extensive research on Diabetes, as well as continuing diabetes education initiatives in India. As a key facet of this dual association, AstraZeneca unveiled a campaign-‘Beyond Sugar’, athree-year patient awareness program developed to benefit over 1 Crorepeople living with Diabetes across the country. This initiative will empower patients/caregivers to have conversations around Diabetes and make informed decisions about the management of the disease.
The International Diabetes Foundation Atlas on Diabetes shows that 1 in 11 people in south Asia have Diabetes and that India will have around 11.5 Crore diabetes patients by 2030. While 10% to 15% of the general population have Diabetes, a recent study suggested that 44% of patients hospitalised for Heart Failure (HF) have type 2 diabetes showcasing the steep correlation between Diabetes and HF. HF is a major health problem in India with post-admission mortality of 20%–30%. Chronic kidney diseases is associated with significant patient death and an increased risk of heart failure. Therefore, it is critical that Diabetes be controlled to decrease the incidence of HF and CKD in India.
Dr.AnilKukreja, Vice President – Medical Affairs & Regulatory, AstraZeneca India, said “AstraZeneca has always been at the forefront of enablingpatient-centric solutions for the management of non-communicable diseases. Despite currently available therapies, the awareness levels among the public is relatively low,resulting in uncontrolled Diabetes and additional complications of the heart and kidneys.The partnership between AstraZeneca and RSSDI will go a long way in supportingpatient-centric digital awareness campaign and programs to raise awareness about Diabetes and its complications so that they can act early to manage or even prevent the complications”.
Dr.BanshiSaboo, President- RSSDI and Organising Chairman 2020, said, “This partnership between RSSDI and AstraZeneca will result in increased awareness levels about Diabetes and its complications. Our vision is to touch 1 Crore lives in India over the next three years through this Digital patient-centric approach. In the COVID era, this digitally-powered initiative will also empower patients/caregivers to have better conversations with their doctors about the disease and make informed decisions in the management of Diabetes. All this will culminate towards shifting from the glucose centric management approach towards a holistic and an early Cardio-Renal focused management of type 2 diabetes.”
Dr. Sanjay Agarwal, Secretary- RSSDI 2020, said, “Being the largest organisation of Diabetes doctors and researchers in Asia, RSSDI is always focused at elevating the patient outcomes in Diabetes with constant research and innovative solutions. Beyond Sugar is one such patient-centric initiative which will play a vital role along with our RSSDI state chapters to raise the awareness by leveraging social media and digital platforms. With the support of AstraZeneca, we aim to reach out to the patients, community and HCP to increase awareness about Diabetes and help patients initiate conversations about the prevention of complications in Diabetes.”
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
About AstraZeneca Pharma India Limited
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
AstraZeneca Pharma India Limited (AZPIL) was established in 1979 and is marking its 40th year of a long-standing commitment to patients in India. It is headquartered at Bengaluru, Karnataka. AstraZeneca India has a workforce of over 1400 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialisation. For more information, please visit: www.astrazeneca.com/india
Media Contact:
Chandrashekar Deshpande | Mobile: 9986713975 | Email: chandrashekhar.deshpande@astrazeneca.com
Arjun Das | Mobile: 9632085332 | Email: arjundas.mp@adfactorspr.com
List Your Business for Free | Login to manage your Business Page
© 2021 educratsweb.com. | Designed & Developed by educratsweb.com Email us at educratsweb@gmail.com
